You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

Claims for Patent: 7,501,400

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,501,400

Title:	Inhibition of gastric acid production and/or secretion
Abstract:	The present invention relates to methods for the treatment or prevention of gastric acid disturbances and for reducing the breakdown of acid sensitive agents in the gastrointestinal tract. The present invention also relates to a method for transfecting parietal cells in vivo. The present invention also relates to synthetic oligonucleotides which may be used in these methods.
Inventor(s):	Tachas; George (Kingsbury, Victoria, 3083, AU)
Assignee:
Application Number:	09/979,666
Patent Claims:	1. A method for decreasing production or secretion of gastric acid in a human subject in need thereof, which method comprises administering to the subject an effective amount of an oligonucleotide capable of reducing or inhibiting gastric acid production or secretion in the subject, wherein said oligonucleotide consists of from 12 to 30 nucleobases and is entirely complementary to a region of an RNA transcript encoding an alpha chain of the human gastric proton pump. 2. A method as claimed in claim 1 wherein the region is selected from the group consisting of: (a) a region involved in translation initiation; (b) a region involved in ribosome attachment to the transcript; (c) a 5' untranslated region; (d) a region encompassing an exon-intron boundary; (e) a coding region; and (f) a 3' untranslated region. 3. A method as claimed in claim 1 wherein the oligonucleotide comprises at least a seven nucleotide portion of (T/U) CA(T/U) AG(T/U) (T/U)C(T/U) CGG CC (T/U)(T/U)C CCC A(T/U) (SEQ ID NO:3). 4. A method as claimed in claim 1 wherein the oligonucleotide has a sequence selected from the group consisting of: AAU UCA TAA TTC TCC TTC CCC AU (SEQ ID NO:5); GUG ATA TAG ATA AGG TAG GG UGU (SEQ ID NO:6); U CAU AGT TCT CGG CC TTC CCC AU (SEQ ID NO:7); U CAU AGT TCT CGG CC UUC CCC AU (SEQ ID NO:8); U CAU AGU UCU CGG CC UUC CCC AU (SEQ ID NO:9); CAU AGU TCT CGG CCT TCC CCA U (SEQ ID NO:10); CAU AGT TCT CGG CCU UCC CCA U (SEQ ID NO:11); CAT AGT TCT CGG CCT TCC CCA T (SEQ ID NO:12); CAT AGT TCT CGG CCT TCC CCA TG (SEQ ID NO:13); CAT AGT TCT CGG CCT TCC CCA TGG (SEQ ID NO:14); CAT AGT TCT CGG CCT TCC CCA TGGT (SEQ ID NO:15); GUG AUG TAG ATG AGG UAG GG (SEQ ID NO:16); CA(T/U) AG(T/U) (T/U)C(T/U) C GGC C(T/U)(T/U) CCC CA(T/U) (SEQ ID NO:17); CA(T/U) AG(T/U) (T/U)C(T/U) C GGC C(T/U)(T/U) CCC C (SEQ ID NO:18); CA(T/U) AG(T/U) (T/U)C(T/U) C GGC C(T/U)(T/U) CC (SEQ ID NO:19); CA(T/U) AG(T/U) (T/U)C(T/U) C GGC C(T/U) (SEQ ID NO:20); and CA(T/U) AG(T/U) (T/U)C(T/U) C GGC C (SEQ ID NO:21). 5. A method as claimed in claim 1 wherein the oligonucleotide comprises at least one modified internucleoside linkage. 6. A method as claimed in claim 1 wherein the oligonucleotide comprises at least one modified sugar moiety. 7. A method as claimed in claim 6 wherein the modified sugar moiety is selected from the group consisting of a 2'-O-propyl sugar moiety, a 2'-O-alkyl sugar moiety, a 2'-O-aminopropyl sugar moiety, a 2'-O-methyl sugar moiety, a 2'-O-methoxyethyl sugar moiety or a 2'-allyl sugar moiety. 8. A method as claimed in claim 1 wherein the oligonucleotide comprises at least one modified nucleobase. 9. A method as claimed in claim 1 wherein the oligonucleotide is conjugated to a delivery agent. 10. A method as claimed in claim 9 wherein the delivery agent is selected from the group consisting of K.sup.+ ions, gastric proton pump inhibitors and agents which bind to parietal cell surface receptors. 11. A method as claimed in claim 1 wherein the oligonucleotide is administered orally. 12. A method as claimed in claim 11 in which the effective amount is administered at a dosing frequency of once every 4 to 7 days. 13. A method as claimed in claim 1 wherein the oligonucleotide is administered in conjunction with a gastric acid neutralizing agent or an agent which interferes with the production or secretion of gastric acid.

Details for Patent 7,501,400

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2020-05-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2020-05-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2020-05-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.